Ironwood Pharmaceuticals, Inc. (IRWD) Given Average Recommendation of “Hold” by Analysts

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) has been assigned a consensus rating of “Hold” from the fourteen ratings firms that are presently covering the firm, Marketbeat.com reports. Three research analysts have rated the stock with a sell rating, seven have given a hold rating and four have issued a buy rating on the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $17.56.

IRWD has been the subject of several analyst reports. Credit Suisse Group initiated coverage on Ironwood Pharmaceuticals in a report on Monday, November 27th. They issued a “buy” rating and a $19.00 target price for the company. Zacks Investment Research upgraded Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, January 18th. Morgan Stanley restated a “hold” rating on shares of Ironwood Pharmaceuticals in a report on Monday, December 4th. ValuEngine upgraded Ironwood Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, November 29th. Finally, BidaskClub lowered Ironwood Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, December 7th.

Shares of Ironwood Pharmaceuticals (NASDAQ IRWD) opened at $13.67 on Friday. Ironwood Pharmaceuticals has a 1-year low of $12.89 and a 1-year high of $19.94. The company has a quick ratio of 4.86, a current ratio of 4.87 and a debt-to-equity ratio of -22.31. The firm has a market capitalization of $2,050.00, a P/E ratio of -14.24 and a beta of 1.28.

In other Ironwood Pharmaceuticals news, insider Mark G. Currie sold 60,000 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Wednesday, January 24th. The stock was sold at an average price of $15.45, for a total value of $927,000.00. Following the transaction, the insider now directly owns 835,000 shares of the company’s stock, valued at approximately $12,900,750. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, CEO Peter M. Hecht sold 113,405 shares of Ironwood Pharmaceuticals stock in a transaction that occurred on Thursday, December 7th. The stock was sold at an average price of $15.12, for a total value of $1,714,683.60. Following the completion of the transaction, the chief executive officer now directly owns 4,696,917 shares in the company, valued at $71,017,385.04. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 174,905 shares of company stock worth $2,666,359. Company insiders own 7.63% of the company’s stock.

A number of hedge funds and other institutional investors have recently modified their holdings of IRWD. Zurcher Kantonalbank Zurich Cantonalbank increased its position in Ironwood Pharmaceuticals by 128.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 9,010 shares of the biotechnology company’s stock worth $135,000 after buying an additional 5,069 shares during the period. Gerber Kawasaki Wealth & Investment Management bought a new stake in shares of Ironwood Pharmaceuticals during the third quarter valued at approximately $170,000. Hemenway Trust Co LLC bought a new stake in shares of Ironwood Pharmaceuticals during the fourth quarter valued at approximately $204,000. Ameritas Investment Partners Inc. increased its position in shares of Ironwood Pharmaceuticals by 5.8% during the second quarter. Ameritas Investment Partners Inc. now owns 11,821 shares of the biotechnology company’s stock valued at $223,000 after purchasing an additional 648 shares during the period. Finally, Virtu KCG Holdings LLC increased its position in shares of Ironwood Pharmaceuticals by 10.3% during the second quarter. Virtu KCG Holdings LLC now owns 15,740 shares of the biotechnology company’s stock valued at $297,000 after purchasing an additional 1,470 shares during the period.

COPYRIGHT VIOLATION WARNING: “Ironwood Pharmaceuticals, Inc. (IRWD) Given Average Recommendation of “Hold” by Analysts” was originally posted by American Banking News and is owned by of American Banking News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright & trademark law. The original version of this piece of content can be accessed at https://www.americanbankingnews.com/2018/02/09/ironwood-pharmaceuticals-inc-irwd-given-average-recommendation-of-hold-by-analysts.html.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a biotechnology company. The Company is advancing product opportunities in areas of unmet need, including irritable bowel syndrome with constipation (IBS C), and chronic idiopathic constipation (CIC), hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease (uncontrolled GERD), and vascular and fibrotic diseases.

Analyst Recommendations for Ironwood Pharmaceuticals (NASDAQ:IRWD)

Receive News & Ratings for Ironwood Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ironwood Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply